CAMBRIDGE, Mass. -- (Business Wire)

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report third quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, November 6, 2014. Subsequently, at 8:00 a.m. Eastern Time, Chris Garabedian, Sarepta’s president and chief executive officer, and Sandy Mahatme, Sarepta’s chief financial officer, will host a conference call to discuss third quarter financial results and to provide a corporate update.

The conference call may be accessed by dialing 800-708-4539 for domestic callers and 847-619-6396 for international callers. The passcode for the call is 38322454. Please specify to the operator that you would like to join the "Sarepta Third Quarter 2014 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward–looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.

Contacts:

Sarepta Investor Contact:
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Sarepta Media Contact:
Tony Plohoros, 908-940-0135
tplohoros@6degreespr.com

Source: Sarepta Therapeutics, Inc.